DNMT3A and acute myeloid leukemia: AML patients with TET2 mutations showed aberrant methylation and expression profiles of SRSF2, ASXL1, RUNX1, DNMT3A, FLT3-ITD, C/EBPalpha, and JAK2 compared to TET2 wild-type AML patients [154].